NIH announces strategy for developing COVID-19 drugs, vaccines
April 21, 2020
Drug companies will collaborate across hundreds of clinical trials in effort to coordinate private coronavirus research, which has been marked by chaos thus far
The National Institutes of Health announced an initiative Friday to unify disparate efforts across the drug industry to respond to the coronavirus-related pandemic.
Pharmaceutical companies will collaborate across hundreds of COVID-19 clinical trials, the NIH says, by sharing “master protocols” on how those clinical trials will work.
“Collaboration is a critical ingredient for success and the FDA will continue to use every tool possible under our Coronavirus Treatment Acceleration Program to speed the development of safe and effective medical countermeasures,” said Food and Drug Administration Commissioner Stephen Hahn in a statement.
The coronavirus-related research race has been thus far marked by chaos as dozens of private companies and researchers compete for a cure, according to a recent news report.
Read the full article by Emily Kopp below.
Recent News
- BioUtah’s 2026 Utah Life Sciences Summit Recap
- 2026 Life Sciences Awards to be Presented at the Mayer Brown Utah Life Sciences Summit
- PROGRESS TRIAL DEMONSTRATES EDWARDS TAVR IS SUPERIOR TO CLINICAL SURVEILLANCE FOR MODERATE AS PATIENTS WITH AT-RISK FEATURES
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
- Utah Business, Government Leaders Deepen Connections in Ireland
- Co-Diagnostics’ Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara’s SARAGENE® Test
